So here's the thing about Tilray Brands Inc. (TLRY): it's trying to do a lot all at once. The company is pushing hard into healthcare, cannabis, and beverages across the globe, which sounds exciting if you're into growth stories. But investors got a bit of a reality check on Wednesday when Tilray said it's planning to sell up to $180 million worth of new shares. That kind of move tends to make existing shareholders nervous—because more shares out there means each one you own is a little less valuable. And sure enough, the stock dipped.
What's all this money for? Well, Tilray is building what it calls a "vertically integrated healthcare ecosystem" in the U.K., thanks to its acquisition of the Lyphe Group. They didn't say how much they paid, but the idea is to get a stronger foothold in medical cannabis over there. Meanwhile, over in the beverage world, they're still working on that BrewDog acquisition from a while back. The goal is to take those drinks international and hopefully start generating positive cash flow by 2027. They're even launching Hi-Ball Energy in the U.K. next month. And in the U.S., they're keeping an eye on the whole medical cannabis rescheduling debate, just in case things open up.
To pay for all this ambition, Tilray filed that $180 million at-the-market equity program, with Jefferies LLC and some partners handling the sales. As of the end of its third fiscal quarter on February 28, 2026, the company had about $264.8 million in cash, restricted cash, and marketable securities. So they're not exactly broke, but growth isn't cheap.
Technical Analysis
Let's talk charts for a second. Tilray is currently trading in the lower part of its 52-week range, which has swung from a high of $23.20 down to a low of $3.51. Right now, it's sitting 4.3% above its 20-day simple moving average—that's a short-term positive sign. But it's also 3.8% below its 50-day SMA, which hints at some intermediate weakness. The longer-term picture looks tougher: the stock is 16.6% below its 100-day SMA and 29.2% below its 200-day SMA, suggesting a bearish trend over time.
The relative strength index (RSI) is at 52.68, basically neutral—no strong momentum either way. The moving average convergence divergence (MACD) is above its signal line, though, which could mean a bullish shift is brewing. Traders are watching $7.00 as a key resistance level (where selling might pick up) and $6.00 as support (where buyers could step in). Over the past 12 months, the stock has returned 46.15%, which is a decent recovery, but it's still way off those old highs. So, there's potential here, but it's a bumpy ride.
Earnings & Analyst Outlook
Tilray is expected to report its next earnings around July 27, 2026. Analysts are looking for earnings per share of 16 cents, down from 20 cents last time, but revenue is estimated to jump to $257.56 million from $224.53 million. The consensus rating is a Buy, with an average price target of $8.50. Recently, Roth Capital upgraded the stock to Buy on April 2, keeping a $10.00 target. TD Cowen also has a Buy rating but lowered its target to $7.00 on March 30. Back in January, Roth Capital had it at Neutral with a $10.00 target. So, opinions are mixed but generally leaning positive.
Market Positioning
In terms of market performance, Tilray shows a momentum score of 13.23, which means it's underperforming the broader market. The overall signal here is weak, pointing to challenges in keeping up momentum in a competitive landscape.
One interesting tidbit: Tilray makes up a hefty 15.49% of the Amplify Alternative Harvest ETF (MJ). That's a big deal because if money flows into or out of that ETF, it forces automatic buying or selling of Tilray shares. So, ETF movements can have a direct, mechanical impact on the stock price.
Price Action
On Wednesday, Tilray Brands shares were down 2.89%, trading at $6.71. That drop lines up with the news of the equity program—investors are clearly weighing the cost of growth against the risk of dilution.
